HYLENEX RECOMBINANT Drug Profile

Summary for Tradename: HYLENEX RECOMBINANT

High Confidence Patents:	4
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for HYLENEX RECOMBINANT

Recent Clinical Trials for HYLENEX RECOMBINANT

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
The Wistar Institute	Phase 1
Pablo Tebas	Phase 1
Inovio Pharmaceuticals	Phase 1

See all HYLENEX RECOMBINANT clinical trials

Pharmacology for HYLENEX RECOMBINANT

Established Pharmacologic Class	Endoglycosidase
Chemical Structure	Glycoside Hydrolases

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for HYLENEX RECOMBINANT Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for HYLENEX RECOMBINANT Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Halozyme Therapeutics, Inc.	HYLENEX RECOMBINANT	hyaluronidase human	Injection	021859		2024-03-05	DrugPatentWatch analysis and company disclosures
Halozyme Therapeutics, Inc.	HYLENEX RECOMBINANT	hyaluronidase human	Injection	021859		2029-02-20	DrugPatentWatch analysis and company disclosures
Halozyme Therapeutics, Inc.	HYLENEX RECOMBINANT	hyaluronidase human	Injection	021859		2029-04-16	DrugPatentWatch analysis and company disclosures
Halozyme Therapeutics, Inc.	HYLENEX RECOMBINANT	hyaluronidase human	Injection	021859		2029-02-20	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for HYLENEX RECOMBINANT Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Halozyme Therapeutics, Inc.	HYLENEX RECOMBINANT	hyaluronidase human	Injection	021859		2037-02-27	Patent claims search
Halozyme Therapeutics, Inc.	HYLENEX RECOMBINANT	hyaluronidase human	Injection	021859		2019-11-29	Patent claims search
Halozyme Therapeutics, Inc.	HYLENEX RECOMBINANT	hyaluronidase human	Injection	021859		2029-03-04	Patent claims search
Halozyme Therapeutics, Inc.	HYLENEX RECOMBINANT	hyaluronidase human	Injection	021859		2031-03-31	Patent claims search
Halozyme Therapeutics, Inc.	HYLENEX RECOMBINANT	hyaluronidase human	Injection	021859		2033-10-16	Patent claims search
Halozyme Therapeutics, Inc.	HYLENEX RECOMBINANT	hyaluronidase human	Injection	021859		2032-10-25	Patent claims search
Halozyme Therapeutics, Inc.	HYLENEX RECOMBINANT	hyaluronidase human	Injection	021859		2032-10-18	Patent claims search

International Patents for HYLENEX RECOMBINANT

Country	Patent Number	Estimated Expiration
Mexico	PA05009429
Cyprus	2016024
South Korea	20110114692
Eurasian Patent Organization	200701791
Denmark	1858926
Portugal	1858926
South Korea	20120094493

Supplementary Protection Certificates for HYLENEX RECOMBINANT

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
92780	Luxembourg		PRODUCT NAME: TRASTUZUMAB ET HYALURONIDASE HUMAINE RECOMBINANTE; FIRST REGISTRATION DATE: 20130826
300822	Netherlands		PRODUCT NAME: RITUXIMAB EN RECOMBINANT HUMAAN HYALURONIDASE; REGISTRATION NO/DATE: EU/1/98/067/003 20140326
CA 2015 00043	Denmark		PRODUCT NAME: TRASTUZUMAB OG REKOMBINANT HUMAN HYALURONIDASE; REG. NO/DATE: C(20135603) /EU/1/00/145/002 20130826
CA 2016 00031	Denmark		PRODUCT NAME: RITUXIMAB AND RECOMBINANT HUMAN HYALURONIDASE; REG. NO/DATE: EU/1/98/067 20140326
122016000049	Germany		PRODUCT NAME: RITUXIMAB UND REKOMBINANTE HUMANE HYALURONIDASE; NAT. REGISTRATION NO/DATE: EU/1/98/067/003 20140321; FIRST REGISTRATION: EU EU/1/98/067/003 20140621
132016000070123	Italy		PRODUCT NAME: RITUXIMAB IN ASSOCIAZIONE CON IALURONIDASI RICOMBINANTE UMANA - SOLUZIONE PER INIEZIONE SOTTOCUTANEA(MABTHERA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/98/067/001-003, 20140326
2015C/044	Belgium		PRODUCT NAME: LA COMBINAISON DE TRASTUZUMAB ET HYALURONIDASE HUMAINE RECOMBINANTE; AUTHORISATION NUMBER AND DATE: EU/1/00/145/002 20130828

HYLENEX RECOMBINANT: Market Dynamics and Financial Trajectory

Last updated: April 25, 2026

What is HYLENEX RECOMBINANT’s market position?

HYLENEX RECOMBINANT is a recombinant hyaluronidase product branded for clinical use in settings where hyaluronidase is used to improve dispersion and absorption of co-administered solutions. The product’s market dynamics are shaped by (1) dosing economics, (2) administration and formulary adoption in infusion and interventional care pathways, (3) competitive branded and authorized-generic alternatives, and (4) payer restrictions tied to coverage evidence.

The core market dynamic is that hyaluronidase products compete on clinical protocol fit and unit economics, not on broad therapeutic replacement. In practice, procurement decisions track:

• Whether the hospital or specialty clinic already stocks alternative hyaluronidase options
• Whether the product can be used within existing infusion room protocols without workflow changes
• Whether payers enforce reimbursement limits tied to diagnosis and billing documentation

How does revenue typically move for this class of drug?

Financial trajectory for specialty biologics marketed through hospital channels usually follows a predictable adoption curve:

• Early period: protocol validation, formulary review cycles, and uptake driven by a limited set of sites
• Growth period: broader distribution and increased patient volume through clinician familiarity and institutional contracting
• Maturity: volume stabilizes; revenue increasingly depends on price per unit, contract renewals, and utilization management
• Downcycle risk: biosimilar or competing products pressure net price, while utilization limits constrain growth

For a biologic like HYLENEX RECOMBINANT, net sales movement is most sensitive to:

• Net price (rebates, discounts, group purchasing organization contracting)
• Purchase order concentration (few large systems can dominate volume)
• Utilization protocols (use in co-administration pathways, order frequency per treated patient, and documented indication rules)

What are the primary demand drivers?

HYLENEX RECOMBINANT demand is driven by institutional adoption in care settings that use hyaluronidase for dispersion and absorption-enhancing protocols. Demand is concentrated in:

• Hospitals and specialty infusion settings where standardized protocols reduce variability
• Procurement channels tied to pharmacy and therapeutics committee decisions
• Clinical sites where hyaluronidase is embedded in order sets

Demand tends to be resilient when:

• Protocols are stable (no major treatment guideline shifts)
• Administered dosing frequency does not materially change
• Competitors do not trigger broad formulary switches

Demand weakens when:

• Competing products win new contracts with lower net price
• Utilization management (prior authorization, documentation edits) restricts eligible use
• Institutions consolidate SKUs to reduce inventory complexity

What are the key headwinds from competition and contracting?

HYLENEX RECOMBINANT’s financial trajectory depends on how quickly competitors gain share in the same hospital pharmacy purchasing lanes. For this category, competition plays out through:

• Formulary status (preferred vs non-preferred)
• Contracting (GPO pricing, systemwide tier placement, conversion incentives)
• Substitution dynamics (therapeutic interchange within hyaluronidase class, subject to payer and institutional rules)

Net price compression is usually the first visible effect of intensified competition. Volume can lag because clinicians often continue using existing inventory until contract renewal or inventory turns complete.

How do reimbursement and policy affect sales stability?

Specialty biologics sold into US hospital systems are highly influenced by reimbursement mechanics:

• Coverage policies that limit eligible diagnoses or require documentation
• Claim edits that reduce reimbursement when documentation does not match payer requirements
• Site-of-care and billing structure that can change effective payment rates

These factors tend to affect utilization before they affect contract pricing, producing a pattern where early declines show up in volume before price follows, or the reverse depending on how contracts are negotiated.

What does the long-run competitive landscape imply for HYLENEX RECOMBINANT?

Across hospital-administered biologics, long-run outcomes typically track the combined effect of:

• Competitor penetration into the same therapeutic protocol niches
• The durability of institution-level formularies
• The ability to retain preferred positioning through contract renewals

For HYLENEX RECOMBINANT, durability hinges on whether it remains the default hyaluronidase within protocols and whether conversion efforts by competitors succeed during renewal windows.

How is the product positioned in labeling and clinical use?

HYLENEX RECOMBINANT is a recombinant hyaluronidase product (FDA-labeled) used in conjunction with co-administered solutions, reflecting the established hyaluronidase role of improving dispersion and absorption of injected fluids. This “adjunct” mechanism shapes the market: it does not replace core therapies, so its commercial pull depends on how often co-administered regimens require hyaluronidase.

What does the product’s safety and use profile do to adoption?

For biologic hospital products, uptake correlates with:

• Low protocol complexity
• Predictable administration
• Manageable safety monitoring burden

A stable safety and administration profile reduces friction in pharmacy and nursing adoption, which is critical for sustaining share once a system standardizes workflows.

---

Market dynamics at a glance

Variable	What it does to demand	What it does to net sales
Hospital formulary adoption	Increases patient access through standardized order sets	Locks in repeat procurement and pricing tiers
GPO and system contracts	Drives volume distribution across large purchasing groups	Compresses net price if competitors undercut tier placement
Utilization management	Limits reimbursable uses, reduces order frequency	Can reduce effective realized revenue even if list price holds
Clinician switching dynamics	Slows down conversion after contract changes due to inventory cycles	Shifts net price impact timing relative to volume impact
Protocol stability	Sustains baseline use rates	Supports predictable contracting leverage

---

Financial trajectory: expected shape under typical biologic life-cycle

Without a product-specific revenue series in the available record, the most reliable way to model financial trajectory is via the standard pattern of hospital specialty biologics tied to formulary and contracting.

1) Ramp and early traction

• Growth comes from formulary conversion and expansion from early adopter sites to larger health systems
• Revenue depends on achieving consistent institutional standing, not on broad geographic spread

2) Maturity

• Share stabilizes; growth slows
• Net sales increasingly depend on net pricing and contract terms at renewal

3) Competitive pressure phase

• Price compression appears first through contract concessions and rebate changes
• Volume follows if the product loses preferred positioning

4) Post-contract dynamics

• Switching takes time due to inventory and workflow
• Net sales can remain supported temporarily even when competitors begin winning share

---

Key business implications for planning and investment

What matters most to profitability

1. Net price retention through contracting: rebates, discounts, and tier placement define realized revenue.
2. Utilization continuity: protocol placement controls order frequency and patient volume.
3. Institution concentration risk: a small number of large systems can swing quarterly results.

What signals share loss early

• Declining orders in large integrated delivery networks
• Tier demotion from preferred to non-preferred status
• Broader substitution within the hyaluronidase class during renewals

What signals share durability

• Continuation of preferred placement across renewal cycles
• Stable utilization documentation patterns
• Consistent purchase order cadence across top accounts

---

Key Takeaways

• HYLENEX RECOMBINANT competes primarily on institutional adoption, protocol fit, and net contracting terms rather than disease-area dominance.
• Its market and financial trajectory should be evaluated through formulary status, GPO contracting, and utilization management, since those variables drive both volume and net price.
• The expected revenue pattern for a hospital-administered specialty biologic is an adoption-led ramp, followed by maturity driven by contract renewals, with competitive pressure causing net price compression first and volume follow-on once switching completes.

---

FAQs

1. Is HYLENEX RECOMBINANT a standalone therapy or an adjunct?
   It is used in conjunction with co-administered solutions, so demand is tied to protocol frequency rather than monotherapy substitution.

2. What most strongly determines hospital ordering behavior?
   Formulary status (preferred vs non-preferred), contract tier placement, and workflow fit in infusion and administration settings.

3. How does competition typically show up in revenue?
   Net price pressure appears first via contracting and rebates; volume declines follow when preferred placement is lost and inventory cycles complete.

4. Why does reimbursement policy matter even if list price stays stable?
   Utilization management and documentation edits affect reimbursable orders, changing realized revenue through reduced eligible use.

5. What’s the most practical lens for forecasting sales?
   Track preferred formulary retention, contract renewal outcomes, and ordering cadence in top integrated health systems.

---

References

[1] FDA. “HYLENEX RECOMBINANT” (prescribing information and related regulatory materials). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/